These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 28085283)

  • 1. Design, Synthesis, and Biological Evaluation of Novel, Non-Brain-Penetrant, Hybrid Cannabinoid CB
    Iyer MR; Cinar R; Katz A; Gao M; Erdelyi K; Jourdan T; Coffey NJ; Pacher P; Kunos G
    J Med Chem; 2017 Feb; 60(3):1126-1141. PubMed ID: 28085283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a Peripherally Restricted Hybrid Inhibitor of CB1 Receptors and iNOS on Alcohol Drinking Behavior and Alcohol-Induced Endotoxemia.
    Santos-Molina L; Herrerias A; Zawatsky CN; Gunduz-Cinar O; Cinar R; Iyer MR; Wood CM; Lin Y; Gao B; Kunos G; Godlewski G
    Molecules; 2021 Aug; 26(16):. PubMed ID: 34443679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral Hybrid CB
    Zawatsky CN; Park JK; Abdalla J; Kunos G; Iyer MR; Cinar R
    Front Endocrinol (Lausanne); 2021; 12():744857. PubMed ID: 34650521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis.
    Cinar R; Iyer MR; Liu Z; Cao Z; Jourdan T; Erdelyi K; Godlewski G; Szanda G; Liu J; Park JK; Mukhopadhyay B; Rosenberg AZ; Liow JS; Lorenz RG; Pacher P; Innis RB; Kunos G
    JCI Insight; 2016 Jul; 1(11):. PubMed ID: 27525312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
    Fong TM; Guan XM; Marsh DJ; Shen CP; Stribling DS; Rosko KM; Lao J; Yu H; Feng Y; Xiao JC; Van der Ploeg LH; Goulet MT; Hagmann WK; Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Francis B; Strack AM; MacIntyre DE; Shearman LP
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1013-22. PubMed ID: 17327489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, Biological Evaluation, and Molecular Modeling Studies of 3,4-Diarylpyrazoline Series of Compounds as Potent, Nonbrain Penetrant Antagonists of Cannabinoid-1 (CB
    Iyer MR; Cinar R; Wood CM; Zawatsky CN; Coffey NJ; Kim KA; Liu Z; Katz A; Abdalla J; Hassan SA; Lee YS
    J Med Chem; 2022 Feb; 65(3):2374-2387. PubMed ID: 35084860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse.
    Vasiljevik T; Franks LN; Ford BM; Douglas JT; Prather PL; Fantegrossi WE; Prisinzano TE
    J Med Chem; 2013 Jun; 56(11):4537-50. PubMed ID: 23631463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CB1 cannabinoid receptor-mediated increases in cyclic AMP accumulation are correlated with reduced Gi/o function.
    Eldeeb K; Leone-Kabler S; Howlett AC
    J Basic Clin Physiol Pharmacol; 2016 May; 27(3):311-22. PubMed ID: 27089415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous Inhibition of Peripheral CB1R and iNOS Mitigates Obesity-Related Dyslipidemia Through Distinct Mechanisms.
    Roger C; Buch C; Muller T; Leemput J; Demizieux L; Passilly-Degrace P; Cinar R; Iyer MR; Kunos G; Vergès B; Degrace P; Jourdan T
    Diabetes; 2020 Oct; 69(10):2120-2132. PubMed ID: 32680936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.
    Yan L; Huo P; Debenham JS; Madsen-Duggan CB; Lao J; Chen RZ; Xiao JC; Shen CP; Stribling DS; Shearman LP; Strack AM; Tsou N; Ball RG; Wang J; Tong X; Bateman TJ; Reddy VB; Fong TM; Hale JJ
    J Med Chem; 2010 May; 53(10):4028-37. PubMed ID: 20423086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual inhibition of cannabinoid CB
    Udi S; Hinden L; Ahmad M; Drori A; Iyer MR; Cinar R; Herman-Edelstein M; Tam J
    Br J Pharmacol; 2020 Jan; 177(1):110-127. PubMed ID: 31454063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenylpyrrole derivatives as neural and inducible nitric oxide synthase (nNOS and iNOS) inhibitors.
    López Cara LC; Camacho ME; Carrión MD; Tapias V; Gallo MA; Escames G; Acuña-Castroviejo D; Espinosa A; Entrena A
    Eur J Med Chem; 2009 Jun; 44(6):2655-66. PubMed ID: 19117642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and biological evaluation of CB1 cannabinoid receptor ligands derived from the 1,5-diarylpyrazole scaffold.
    Tu G; Xiong F; Huang H; Kuang B; Li S
    J Enzyme Inhib Med Chem; 2011 Apr; 26(2):222-30. PubMed ID: 20565336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s).
    Kulkarni PM; Kulkarni AR; Korde A; Tichkule RB; Laprairie RB; Denovan-Wright EM; Zhou H; Janero DR; Zvonok N; Makriyannis A; Cascio MG; Pertwee RG; Thakur GA
    J Med Chem; 2016 Jan; 59(1):44-60. PubMed ID: 26529344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, biological properties, and molecular modeling investigations of novel tacrine derivatives with a combination of acetylcholinesterase inhibition and cannabinoid CB1 receptor antagonism.
    Lange JH; Coolen HK; van der Neut MA; Borst AJ; Stork B; Verveer PC; Kruse CG
    J Med Chem; 2010 Feb; 53(3):1338-46. PubMed ID: 20047331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoid CB1 receptor overactivity contributes to the pathogenesis of idiopathic pulmonary fibrosis.
    Cinar R; Gochuico BR; Iyer MR; Jourdan T; Yokoyama T; Park JK; Coffey NJ; Pri-Chen H; Szanda G; Liu Z; Mackie K; Gahl WA; Kunos G
    JCI Insight; 2017 Apr; 2(8):. PubMed ID: 28422760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of diacylglycerol lipase in constitutive and angiotensin AT1 receptor-stimulated cannabinoid CB1 receptor activity.
    Turu G; Simon A; Gyombolai P; Szidonya L; Bagdy G; Lenkei Z; Hunyady L
    J Biol Chem; 2007 Mar; 282(11):7753-7. PubMed ID: 17227758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of urea and thiourea kynurenamine derivatives: synthesis, molecular modeling, and biological evaluation as nitric oxide synthase inhibitors.
    Chayah M; Carrión MD; Gallo MA; Jiménez R; Duarte J; Camacho ME
    ChemMedChem; 2015 May; 10(5):874-82. PubMed ID: 25801086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological comparison of traditional and non-traditional cannabinoid receptor 1 blockers in rodent models in vivo.
    Varga B; Kassai F; Szabó G; Kovács P; Fischer J; Gyertyán I
    Pharmacol Biochem Behav; 2017 Aug; 159():24-35. PubMed ID: 28666894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioisosteric replacements of the pyrazole moiety of rimonabant: synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists.
    Lange JH; van Stuivenberg HH; Coolen HK; Adolfs TJ; McCreary AC; Keizer HG; Wals HC; Veerman W; Borst AJ; de Looff W; Verveer PC; Kruse CG
    J Med Chem; 2005 Mar; 48(6):1823-38. PubMed ID: 15771428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.